Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50 versus HYDRODIURIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50 versus HYDRODIURIL.
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50 vs HYDRODIURIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle via mechanisms involving interference with calcium ion movement and possibly nitric oxide release. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water, reducing plasma volume and cardiac output.
1 tablet (hydralazine 50 mg/hydrochlorothiazide 50 mg) orally twice daily, maximum 2 tablets daily.
25-100 mg orally once daily. For hypertension: 12.5-25 mg once daily.
None Documented
None Documented
Hydralazine: 2-8 hours (acetylator phenotype dependent; slow acetylators up to 8h, fast acetylators 1-2h). Hydrochlorothiazide: 6-15 hours (mean 10h).
Terminal elimination half-life is approximately 5.6–14.8 hours (mean ~10 hours); clinically, duration of diuresis correlates with half-life, allowing once or twice daily dosing.
Hydralazine: 80% renal (mainly as metabolites, 1-2% unchanged), 10% fecal. Hydrochlorothiazide: >95% renal (unchanged) via organic anion transporters.
Renal: approximately 95% eliminated unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic